Karen Anstey
speaker
48 appearances
1 recordings
1 series
first heard Sep 2020
last heard Sep 2020
Karen Anstey’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
really good question.
No.
So our trial, like also the finger trial, which is the very famous multi-domain trial, had poor adherence to brain training.
So what we find is, and we've seen this in other studies as well, people start off very enthusiastic, but they get bored with it.
So we had about a 20% adherence to the full program of brain training.
Most people started the brain training, but they didn't stick with it.
So this trial showed that the people who received the more intensive intervention, they had cognitive improvement at a six-month follow-up.
Yeah, so what we see with cognition is that when we repeat tests, people do better from practice effects.
So we tend to see a slight improvement over a period of six months.
And in normal aging where people with cognitive impairment, we'd be seeing a decline.
Yes, it was a short time, but this is an at-risk group where we're seeing – the reason this particular trial was targeting this group is that we do see conversion from these conditions into dementia.
So people with mild cognitive impairment have a 5% to 10% chance of progressing to dementia within 12 months.
People with subjective cognitive decline have twice the risk of developing mild cognitive impairment.
So this is a group sort of who are at risk of transitioning fairly quickly, which is why they're a key group for intervention.
That's a very good question about this whole multi-domain approach.
So what's happened in the field of dementia risk reduction is that people did focus on individual risk factors like physical activity, diet, et cetera, and we're at the point now where we do have evidence.
We've got the WHO guidelines for dementia
based on the intervention evidence for each of these individual risk factors but the consensus has been that we really need to target more than one risk factor at a time because we don't know exactly which risk factor is salient for which person and we think we'll get a much bigger effect if we target everything at once.
That does mean we can't then go back and unpack and work out for which person which risk factor was important.
So that's a risk score that I led the development of that was based on data synthesis.
Showing 21–40 of 48 · page 2 of 3
← Previous
Next →